The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction: The Aldo-DHF Randomized Controlled Trial
Abstract
IMPORTANCE: Diastolic heart failure (ie, heart failure with preserved ejection fraction) is a common condition without established therapy, and aldosterone stimulation may contribute to its progression. OBJECTIVE: To assess the efficacy and safety of long-term aldosterone receptor blockade in heart failure with preserved ejection fraction. The primary objective was to determine whether spironolactone is superior to placebo in improving diastolic function and maximal exercise capacity in patients with heart failure with preserved ejection fraction. DESIGN AND SETTING: The Aldo-DHF trial, a multicenter, prospective, randomized, double-blind, placebo-controlled trial conducted between March 2007 and April 2012 at 10 sites in Germany and Austria that included 422 ambulatory patients (mean age, 67 [SD, 8] years; 52% female) with chronic New York Heart Association class II or III heart failure, preserved left ventricular ejection fraction of 50% or greater, and evidence of diastolic dysfunction. INTERVENTION: Patients were randomly assigned to receive 25 mg of spironolactone once daily (n=213) or matching placebo (n=209) with 12 months of follow-up. MAIN OUTCOME MEASURES: The equally ranked co-primary end points were changes in diastolic function (E/e') on echocardiography and maximal exercise capacity (peak VO2) on cardiopulmonary exercise testing, both measured at 12 months. RESULTS: Diastolic function (E/e') decreased from 12.7 (SD, 3.6) to 12.1 (SD, 3.7) with spironolactone and increased from 12.8 (SD, 4.4) to 13.6 (SD, 4.3) with placebo (adjusted mean difference, -1.5; 95% CI, -2.0 to -0.9; P < .001). Peak VO2 did not significantly change with spironolactone vs placebo (from 16.3 [SD, 3.6] mL/min/kg to 16.8 [SD, 4.6] mL/min/kg and from 16.4 [SD, 3.5] mL/min/kg to 16.9 [SD, 4.4] mL/min/kg, respectively; adjusted mean difference, +0.1 mL/min/kg; 95% CI, -0.6 to +0.8 mL/min/kg; P = .81). Spironolactone induced reverse remodeling (left ventricular mass index declined; difference, -6 g/m2; 95% CI, -10 to-1 g/m2; P = .009) and improved neuroendocrine activation (N-terminal pro-brain-type natriuretic peptide geometric mean ratio, 0.86; 95% CI, 0.75-0.99; P = .03) but did not improve heart failure symptoms or quality of life and slightly reduced 6-minute walking distance (-15 m; 95% CI, -27 to -2 m; P = .03). Spironolactone also modestly increased serum potassium levels (+0.2 mmol/L; 95% CI, +0.1 to +0.3; P < .001) and decreased estimated glomerular filtration rate (-5 mL/min/1.73 m2; 95% CI, -8 to -3 mL/min/1.73 m2; P < .001) without affecting hospitalizations. CONCLUSIONS AND RELEVANCE: In this randomized controlled trial, long-term aldosterone receptor blockade improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life in patients with heart failure with preserved ejection fraction. Whether the improved left ventricular function observed in the Aldo-DHF trial is of clinical significance requires further investigation in larger populations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: ISRCTN94726526; Eudra-CT No: 2006-002605-31.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
(1992) · PubMed · Cited by 33,716
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802 · cited 1×
“Minnesota Living With Heart Failure Questionnaire total score 21 (18-23) 21 (19-24) 0.”
BackgroundThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Ommen, S. R., Nishimura, R. A., Appleton, C. P., Miller, F. A., Oh, J. K., Redfield, M. M., & Tajik, A. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1788 · Cited by 2,790
Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P., Smiseth, O. A., De Keulenaer, G., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,679
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Irbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Solomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationHeart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Borlaug, B. A., & Paulus, W. J. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq426 · Cited by 1,093
Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 947
Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00071-2 · Cited by 862
Pitt, B., Wj, R., Zannad, F. M., Neaton, J. D., Martínez, F. A., Roniker, B., Bittman, R. M., Hurley, S., Kleiman, J. H., & Gatlin, M. R. (2003) · Cited by 708
Ather, S., Chan, W., Bozkurt, B., Aguilar, D., Ramasubbu, K., Zachariah, A. A., Wehrens, X. H. T., & Deswal, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.040 · Cited by 693
Rector, T. S., Kubo, S. H., & Cohn, J. N. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90582-w · Cited by 503
Yusuf, S., Pfeffer, Swedberg, K. B., Granger, C. B., Held, P. H., McMurray, J. J. V., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · Cited by 431
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Ahmed, A., Rich, M. W., Love, T. E., Lloyd-Jones, D. M., Aban, I. B., Colucci, W. S., Adams, K. F., & Gheorghiade, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi687 · Cited by 407
Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01116-0 · Cited by 363
Solomon, S. D., Janardhanan, R., Verma, A., Bourgoun, M., Daley, W. L., Purkayastha, D., Lacourcière, Y., Hippler, S. E., Fields, H., Naqvi, T. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60980-5 · Cited by 329
Death in Heart Failure: A Community Perspective
Henkel, D. M., Redfield, M. M., Weston, S. A., Gerber, Y., & Roger, V. L. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.107.743146 · Cited by 286
Mottram, P. M., Haluska, B., Leano, R., Cowley, D., Stowasser, M., & Marwick, T. H. (2004) · Circulation · doi:10.1161/01.cir.0000138680.89536.a9 · Cited by 278
Desai, A. S., Lewis, E. F., Li, R., Solomon, S. D., Assmann, S. F., Boineau, R., Clausell, N., Diaz, R., Fleg, J. L., Gordeev, I., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.09.007 · Cited by 274
Anand, I. S., Rector, T. S., Cleland, J. G., Kuskowski, M., McKelvie, R. S., Persson, H., McMurray, J. J., Zile, M. R., Komajda, M., Massie, B. M., et al. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.962654 · Cited by 249
Deswal, A., Richardson, P., Bozkurt, B., & Mann, D. L. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.04.007 · Cited by 210
Conraads, V. M., Metra, M., Kamp, O., De Keulenaer, G. W., Pieske, B., Zamorano, J., Vardas, P. E., Böhm, M., & Dei Cas, L. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr161 · Cited by 210
Self-citationCampbell, R. T., Jhund, P. S., Castagno, D., Hawkins, N. M., Petrie, M. C., & McMurray, J. J. V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.064 · Cited by 179
Bauersachs, J. K., Heck, M., Fraccarollo, D., Hildemann, S. K., Ertl, G., Wehling, M., & Christ, M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01729-6 · Cited by 167
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats
Lacolley, P. J., Safar, M. E., Lucet, B., Dudal, K. L., Labat, C., & Bénétos, A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01129-3 · Cited by 149
Holland, D. J., Kumbhani, D. J., Ahmed, S. H., & Marwick, T. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.057 · Cited by 140
Chan, A. K.-Y., Sanderson, J. E., Wang, T., Lam, W. W. M., Yip, G. W., Wang, M., Lam, Y., Zhang, Y., Yeung, L. Y. C., Wu, E. B., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.062 · Cited by 133
Kitzman, D. W., Hundley, W. G., Brubaker, P. H., Morgan, T. M., Moore, J. B., Stewart, K. P., & Little, W. C. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.898916 · Cited by 131
Edelmann, F., Stahrenberg, R., Gelbrich, G., Durstewitz, K., Angermann, C. E., Düngen, H., Scheffold, T., Zugck, C., Maisch, B., Regitz‐Zagrosek, V., et al. (2011) · Clinical Research in Cardiology · doi:10.1007/s00392-011-0305-4 · Cited by 128
Self-citationEdelmann, F., Tomaschitz, A., Wachter, R., Gelbrich, G., Knoke, M., Düngen, H., Pilz, S., Binder, L., Stahrenberg, R., Schmidt, A. G., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr292 · Cited by 94
Self-citationEdelmann, F., Schmidt, A. G., Gelbrich, G., Binder, L., Herrmann‐Lingen, C., Halle, M., Hasenfuss, G. P., Wachter, R., & Pieske, B. M. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq087 · Cited by 79
Self-citationVizzardi, E., D’Aloia, A., Giubbini, R., Bordonali, T., Bugatti, S., Pezzali, N., Romeo, A. M., Dei, A., Metra, M., & Cas, L. D. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.052 · Cited by 76
Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications
Iellamo, F., Rosano, G. M. C., & Volterrani, M. (2010) · Current Heart Failure Reports · doi:10.1007/s11897-010-0008-6 · Cited by 28
Phelan, D. M. J., Thavendiranathan, P., Collier, P. H., & Marwick, T. H. (2012) · Heart · doi:10.1136/heartjnl-2012-302178 · Cited by 27
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Metadata
- Authors
- Edelmann, F., Wachter, R., Schmidt, A. G., Kraigher-Krainer, E., Colantonio, C., Kamke, W., Duvinage, A., Stahrenberg, R., Durstewitz, K., Löffler, M., Düngen, H.-D., Tschöpe, C., Herrmann-Lingen, C., Halle, M., Hasenfuss, G., Gelbrich, G., Pieske, B., & Aldo-DHF Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-02-27
- Volume
- 309
- Issue
- 8
- Pages
- 781
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2113829060
- Cited by
- 746
- References
- 47
- FWCI
- 52.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.